Literature DB >> 2963334

CD8+ T cells (cytotoxic/suppressors) are required for protection in mice immunized with malaria sporozoites.

W R Weiss1, M Sedegah, R L Beaudoin, L H Miller, M F Good.   

Abstract

In recent malaria sporozoite vaccine trials in humans and mice, antibodies to the sporozoite coat protein have given only modest protection against sporozoite challenge. In contrast, irradiated sporozoites can protect mice against massive sporozoite infections. Evidence suggests that immunity in these mice is mediated by T cells. To identify the mechanism of immunity, we used monoclonal antibodies specific for either the CD4 or CD8 molecule to selectively deplete sporozoite-immunized mice of T-cell subsets. Though in vivo depletion of CD4+ T cells did not reduce immunity, depletion of CD8+ T cells abolished protection. Monoclonal antibody treatment did not affect anti-sporozoite antibody levels. Our data indicate that cytotoxic T cells are critical for immunity to large numbers of sporozoites and suggest that vaccine development should be reoriented toward stimulating cellular as well as humoral immunity.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2963334      PMCID: PMC279593          DOI: 10.1073/pnas.85.2.573

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  42 in total

1.  Immunity to sporozoite-induced malaria infeciton in mice. I. The effect of immunization of T and B cell-deficient mice.

Authors:  D H Chen; R E Tigelaar; F I Weinbaum
Journal:  J Immunol       Date:  1977-04       Impact factor: 5.422

2.  Plasmodium berghei: T cell dependence of sporozoite-induced immunity in rodents.

Authors:  G L Spitalny; J P Verhave; J H Meuwissen; R S Nussenzweig
Journal:  Exp Parasitol       Date:  1977-06       Impact factor: 2.011

3.  Letter: Sporozoite induced immunity in man against an Ethiopian strain of Plasmodium falciparum.

Authors:  K H Rieckmann; P E Carson; R L Beaudoin; J S Cassells; K W Sell
Journal:  Trans R Soc Trop Med Hyg       Date:  1974       Impact factor: 2.184

4.  Immunization of man against sporozite-induced falciparum malaria.

Authors:  D F Clyde; H Most; V C McCarthy; J P Vanderberg
Journal:  Am J Med Sci       Date:  1973-09       Impact factor: 2.378

Review 5.  Xenogeneic monoclonal antibodies to mouse lymphoid differentiation antigens.

Authors:  J A Ledbetter; L A Herzenberg
Journal:  Immunol Rev       Date:  1979       Impact factor: 12.988

6.  Protective immunity produced by the injection of x-irradiated sporozoites of Plasmodium berghei. II. Effects of radiation on sporozoites.

Authors:  J P Vanderberg; R S Nussenzweig; H Most; C G Orton
Journal:  J Parasitol       Date:  1968-12       Impact factor: 1.276

7.  Studies on the transfer of protective immunity with lymphoid cells from mice immune to malaria sporozoites.

Authors:  J P Verhave; G T Strickland; H A Jaffe; A Ahmed
Journal:  J Immunol       Date:  1978-09       Impact factor: 5.422

8.  Qat-4 and Qat-5, new murine T-cell antigens governed by the Tla region and identified by monoclonal antibodies.

Authors:  G J Hämmerling; U Hämmerling; L Flaherty
Journal:  J Exp Med       Date:  1979-07-01       Impact factor: 14.307

9.  Safety and immunogenicity in man of a synthetic peptide malaria vaccine against Plasmodium falciparum sporozoites.

Authors:  D A Herrington; D F Clyde; G Losonsky; M Cortesia; J R Murphy; J Davis; S Baqar; A M Felix; E P Heimer; D Gillessen
Journal:  Nature       Date:  1987 Jul 16-22       Impact factor: 49.962

10.  Immunization of dissociated spleen cell cultures from normal mice.

Authors:  R I Mishell; R W Dutton
Journal:  J Exp Med       Date:  1967-09-01       Impact factor: 14.307

View more
  196 in total

1.  HLA-A*01-restricted cytotoxic T-lymphocyte epitope from the Plasmodium falciparum circumsporozoite protein.

Authors:  A Kumar; S Kumar; T P Le; S Southwood; J Sidney; J Cohen; A Sette; S L Hoffman
Journal:  Infect Immun       Date:  2001-04       Impact factor: 3.441

2.  Dendritic cells can initiate protective immune responses against malaria.

Authors:  O Bruña-Romero; A Rodriguez
Journal:  Infect Immun       Date:  2001-08       Impact factor: 3.441

Review 3.  Molecular parasitology: progress towards the development of vaccines for malaria, filariasis, and schistosomiasis.

Authors:  S J Cryz
Journal:  Experientia       Date:  1991-02-15

4.  Genetic restriction of protective immunity to Plasmodium yoelii sporozoites.

Authors:  W R Weiss; M F Good; M R Hollingdale; L H Miller; J A Berzofsky
Journal:  Bull World Health Organ       Date:  1990       Impact factor: 9.408

5.  Laser mimicking mosquito bites for skin delivery of malaria sporozoite vaccines.

Authors:  Chang Zhou; Xinyuan Chen; Qi Zhang; Ji Wang; Mei X Wu
Journal:  J Control Release       Date:  2015-02-25       Impact factor: 9.776

Review 6.  Building better T-cell-inducing malaria vaccines.

Authors:  Stephen M Todryk; Michael Walther
Journal:  Immunology       Date:  2005-06       Impact factor: 7.397

7.  Treatment of encephalomyocarditis virus-induced central nervous system demyelination with monoclonal anti-T-cell antibodies.

Authors:  S Sriram; D J Topham; S K Huang; M Rodriguez
Journal:  J Virol       Date:  1989-10       Impact factor: 5.103

8.  Mice deficient in interleukin-4 (IL-4) or IL-4 receptor alpha have higher resistance to sporozoite infection with Plasmodium berghei (ANKA) than do naive wild-type mice.

Authors:  Michael Saeftel; Andreas Krueger; Sandra Arriens; Volker Heussler; Paul Racz; Bernhard Fleischer; Frank Brombacher; Achim Hoerauf
Journal:  Infect Immun       Date:  2004-01       Impact factor: 3.441

9.  Advances and challenges in malaria vaccine development.

Authors:  Ruobing Wang; Joseph D Smith; Stefan H I Kappe
Journal:  Expert Rev Mol Med       Date:  2009-12-16       Impact factor: 5.600

10.  Irradiated sporozoite vaccine induces HLA-B8-restricted cytotoxic T lymphocyte responses against two overlapping epitopes of the Plasmodium falciparum sporozoite surface protein 2.

Authors:  B Wizel; R A Houghten; K C Parker; J E Coligan; P Church; D M Gordon; W R Ballou; S L Hoffman
Journal:  J Exp Med       Date:  1995-11-01       Impact factor: 14.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.